Source: European Medicines Agency (EU) Revision Year: 2021 Publisher: Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050, Bruxelles, Belgium
CONBRIZA 20 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. White to off-white, capsule-shaped, film-coated tablet debossed on one side with “WY20”. The tablet is approximately 1.5 cm in length. |
Each film-coated tablet contains bazedoxifene acetate equivalent to 20 mg bazedoxifene.
Excipient with known effect: Each film-coated tablet contains 142.8 mg lactose (as monohydrate).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Bazedoxifene |
|
| List of Excipients |
|---|
|
Tablet core: Lactose monohydrate Film coating: Hypromellose |
PVC/Aclar blister packs of 7, 28, 30, 84, and 90 film-coated tablets.
Not all pack sizes may be marketed.
Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050, Bruxelles, Belgium
EU/1/09/511/001
EU/1/09/511/002
EU/1/09/511/003
EU/1/09/511/004
EU/1/09/511/005
Date of first authorisation: 17 April 2009
Date of latest renewal: 17 April 2014
| Drug | Countries | |
|---|---|---|
| CONBRIZA | Austria, Cyprus, Estonia, Spain, Croatia, Ireland, Lithuania, Netherlands, Poland |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
